Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:DARA

(DARA) (DARA) Stock Price, News & Analysis

(DARA) logo

About (DARA) Stock (NASDAQ:DARA)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.32
$0.33
52-Week Range
N/A
Volume
13,850 shs
Average Volume
118,843 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

DARA BioSciences Inc is specialty pharmaceutical company based in the United States. The Company's primary focus is on the commercialization of oncology treatment and oncology supportive care pharmaceutical products, including Soltamox, an oral solution of tamoxifen citrate; cancer support therapeutics, including Gelclair, indicated for the treatment of oral mucositis and Bionect, for the management of irritation of the skin as well as first and second degree burns, and Three Mission Pharmacal products, including Ferralet 90 (for anemia), Binosto (alendronate sodium effervescent tablet indicated for the treatment of osteoporosis) and Aquoral (for cancer related dry mouth). The Company has a clinical development asset, KRN5500, which is a Phase II product candidate targeted for treating cancer patients with painful treatment-refractory chronic chemotherapy induced peripheral neuropathy. The Company is a subsidiary of Midatech Pharma Plc.

Receive DARA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (DARA) and its competitors with MarketBeat's FREE daily newsletter.

DARA Stock News Headlines

Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
See More Headlines

DARA Stock Analysis - Frequently Asked Questions

(DARA) (NASDAQ:DARA) released its quarterly earnings data on Monday, November, 2nd. The specialty pharmaceutical company reported ($0.14) earnings per share for the quarter, meeting the consensus estimate of ($0.14). The specialty pharmaceutical company earned $1.18 million during the quarter, compared to the consensus estimate of $0.83 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that (DARA) investors own include Castleton Technology (CTP), Richland Resources Ltd (RLD.L) (RLD), Thor Energy (THR), Global Invacom Group (GINV), Legendary Investments (LEG), iPass (IPAS) and Aeterna Zentaris (AEZS).

Company Calendar

Last Earnings
11/02/2015
Today
5/11/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:DARA
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

This page (NASDAQ:DARA) was last updated on 5/12/2025 by MarketBeat.com Staff
From Our Partners